BRIEF—Positive data for Herceptin biosimilar

South Korea’s Samsung Bioepis has announced positive data from a three-year follow-up comparing Ontruzant (trastuzumab) with its reference biologic, Herceptin.

The study enrolled people with early or locally advanced HER2-positive breast cancer. Overall survival was 97% in the biosimilar trastuzumab group and 93.6% in the reference medicine group.

The data were presented at the St. Gallen International Breast Cancer Conference 2019, in Vienna, Austria.